Generic Name and Formulations:
Glipizide 2.5mg, 5mg, 10mg; ext-rel tabs.
Adjunct to diet and exercise in type 2 diabetes mellitus. Limitations of use: not for treating type 1 diabetes or diabetic ketoacidosis.
Not for treating type 1 diabetes or diabetic ketoacidosis.
Swallow whole. Initially 5mg daily with breakfast. Usual range: 5–10mg once daily; max 20mg daily. Elderly, renal or hepatic impairment: initially 2.5mg. Concomitant other hypoglycemics or transferring to Glucotrol XL: see full labeling.
Type 1 diabetes, diabetic ketoacidosis, with or without coma. Sulfonamide allergy.
Increased risk of cardiovascular mortality. Adrenal or pituitary insufficiency. Stress. Secondary failure may occur with extended therapy. Risk of hemolytic anemia in G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine and blood glucose. Impaired GI function or GI narrowing (XL); avoid. Discontinue if jaundice occurs or skin reactions persist. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. Renal or hepatic impairment (see Adult). Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended.
May be potentiated by concomitant oral miconazole, fluconazole, or drugs affecting glucose metabolism (eg, ACEIs, ARBs, NSAIDs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, quinolones); monitor closely for hypoglycemia with co-administration and for worsening glycemic control upon withdrawal (see full labeling). May be antagonized by atypical antipsychotics, diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers, isoniazid, protease inhibitors; monitor. May be antagonized by colesevelam; administer glipizide ≥4hrs prior to colesevelam. β-blockers, clonidine, guanethidine, reserpine may mask hypoglycemia. Disulfiram-like reaction with alcohol (rare). Monitor for 1–2 weeks if transferring from long-acting sulfonylureas.
Sulfonylurea (2nd generation).
Hypoglycemia, tremor, asthenia, diarrhea, flatulence, allergic skin reactions, photosensitivity, blood dyscrasias, hyponatremia, dizziness, drowsiness, headache; rare: cholestatic jaundice, hepatic porphyria.
XL tabs 2.5mg—30; 5mg, 10mg—100, 500; Tabs—100
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...